Brookline Capital Management Predicts KYMR Q3 Earnings

Key Points

• Brookline Capital Management has revised its Q3 2025 earnings estimate for Kymera Therapeutics to ($0.86) per share, up from a previous estimate of ($0.92).
• Kymera Therapeutics reported Q2 earnings on August 11, showing a loss of ($0.95) per share, which missed the consensus estimate of ($0.83), alongside a revenue of $11.48 million.
• A significant transaction occurred when CEO Nello Mainolfi sold 30,000 shares at an average price of $49.00, resulting in a 4.34% decrease in his ownership stake in the company.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Brookline Capital Management increased their Q3 2025 earnings estimates for shares of Kymera Therapeutics in a research report issued to clients and investors on Monday, August 11th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($0.86) per share for the quarter, up from their previous estimate of ($0.92). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.69) EPS and FY2029 earnings at ($5.13) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million for the quarter, compared to analyst estimates of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The company's revenue was down 55.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.58) EPS.

A number of other research analysts have also recently commented on the stock. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 15th. B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price on the stock in a research report on Wednesday, July 30th. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price on the stock in a research report on Monday, June 2nd. Finally, Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price on the stock. Two analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Kymera Therapeutics has an average rating of "Buy" and a consensus price target of $59.11.

Kymera Therapeutics Trading Up 2.2%

Shares of KYMR stock opened at $40.73 on Thursday. The company's 50-day moving average price is $44.86 and its 200-day moving average price is $36.48. Kymera Therapeutics has a twelve month low of $19.44 and a twelve month high of $53.27. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -11.74 and a beta of 2.18.

Insider Activity

In related news, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. In the last three months, insiders sold 48,349 shares of company stock valued at $2,334,301. 16.01% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in KYMR. Wells Fargo & Company MN increased its stake in shares of Kymera Therapeutics by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after buying an additional 7,487 shares during the period. Summit Investment Advisors Inc. increased its stake in Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the last quarter. PEAK6 LLC purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $302,000. First Trust Advisors LP increased its stake in Kymera Therapeutics by 43.2% in the fourth quarter. First Trust Advisors LP now owns 176,220 shares of the company's stock valued at $7,089,000 after purchasing an additional 53,175 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Kymera Therapeutics in the fourth quarter valued at approximately $251,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.